Prinomastat: combined with antineoplastics increases VTE

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1414, 2003-01, pp. : 22-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

VTE after orthopaedic surgery increases LOS, costs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 388, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Combined hormone therapy and cardiovascular, VTE risk

By  

Reactions Weekly, Vol. 1, Iss. 1161, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Combined hormone therapy and cardiovascular, VTE risk

By  

Inpharma, Vol. 1, Iss. 1597, 2007-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma

By Heath Elisabeth   Burtness Barbara   Kleinberg Lawrence   Salem Ronald   Yang Stephen   Heitmiller Richard   Canto Marcia   Knisely Jonathan   Topazian Mark   Montgomery Elizabeth   Tsottles Nancy   Pithavala Yazdi   Rohmiller Bridget   Collier Mary   Forastiere Arlene  

Investigational New Drugs, Vol. 24, Iss. 2, 2006-03 ,pp. : 135-140

Springer Publishing Company

Access to resources Recommend Favorite

Antineoplastics/pirarubicin: Panhypogammaglobulinaemia following rituximab combined chemotherapy (first report with pirarubicin and procarbazine): case report

By  

Reactions Weekly, Vol. 1, Iss. 1304, 2010-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite